The strong Q2 beat and raised full-year guidance, combined with improving leverage metrics and a key FDA MRTP authorization for ZYN, reinforce the smoke-free transition thesis. Traders should watch for continued IQOS momentum outside Japan/Poland and the impact of accelerated U.S. investments in H2, which could pressure near-term margins but support long-term brand value. The Q3 guidance of $2.20-$2.25 provides a clear near-term catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 22 $194.30entry
- T+1 · 4mo ago −1.64%α −0.40% · $191.12
- T+5 · 4mo ago +2.13%α +4.53% · $198.44
- T+20 · 3mo ago −2.25%α −5.15% · $189.93
- T+60 · 5w ago +2.88%α −0.38% · $199.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PMI reported Q2 2026 adjusted diluted EPS of $2.20, a 15.2% increase YoY and well above the $2.04 consensus, driven by strong smoke-free revenue growth (up 11.7% reported, 9.7% organically) and robust pricing in combustibles. However, reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of its RBH equity investment. The company updated its full-year adjusted EPS forecast to $8.26-$8.41, representing 9.5%-11.5% growth, and guided Q3 adjusted EPS of $2.20-$2.25, both above current Street expectations, reinforcing a positive operational trajectory despite currency headwinds.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted diluted EPS of $2.20 grew 15.2% YoY, beating the $2.04 consensus.
- Total net revenues reached a record $11.2 billion, up 10.4% reported (7.6% organically), with smoke-free now ~42% of total.
- Full-year 2026 adjusted diluted EPS forecast raised to $8.26-$8.41 (9.5%-11.5% growth), above the prior implied consensus.
- Q3 2026 adjusted EPS guided to $2.20-$2.25, above the $2.04 consensus for the next quarter.
- Reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of the RBH (Canada) equity investment.
- International Smoke-Free segment net revenues grew 14.2% (11.8% organically), driven by 8.0% volume growth and strong IQOS performance.
- Net debt to adjusted EBITDA improved to 2.35x from 2.53x at year-end 2025, targeting ~2.0x by year-end.
- FDA granted MRTP authorization to 20 ZYN variants on June 30, the first and only for a nicotine pouch product.
Financial Impact
Q2 adjusted EPS beat consensus by ~7.8% ($2.20 vs $2.04), with full-year guidance raised to $8.26-$8.41, implying ~$0.22 above the prior implied consensus at the midpoint.
Risk Factors
- Currency headwinds: full-year currency impact revised to $0.15 favorable (down from $0.20), with Q3 expected to face an $0.08 unfavorable impact.
- U.S. segment weakness: net revenues declined 0.7% in Q2 and 16.1% YTD, with adjusted OCI down 19.1% organically in Q2 due to investments and manufacturing costs.
- Japan and Poland headwinds: excise-driven price increases in Japan and a flavor ban in Poland are creating transient volume pressure on IQOS HTU.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-049107 |
| Document: earningsreleasepm-ex991xq2.htm | 0001628280-26-049107 |
| Document: pm-20260722.htm | 0001628280-26-049107 |
| Document: 0001628280-26-049107-index-headers.html | 0001628280-26-049107 |
| Document: 0001628280-26-049107-index.html | 0001628280-26-049107 |
| Document: 0001628280-26-049107.txt | 0001628280-26-049107 |
| 8-K Data (Synthetic) | 0001628280-26-049107 |
Track record
14 reports on PM
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.16% at T+20 after the Apr 22, 2026 report. 3 of 3 went positive at some point.
Filters
- Oct 29, 202619d ago Institutional Cluster Neutral 3/10 Entry $208.50 to $201.50 Now $194.38 −6.77% ▼ −3.36% +1.37% vs SPY
- Oct 21, 202627d ago 8-K Neutral 5/10 Entry $197.46 to $202.62 Now $194.38 −1.56% ▲ +2.61% +3.06% vs SPY
- Sep 18, 20268w ago 8-K Bullish 4/10 Entry $188.62 to $190.48 Now $194.38 +3.05% ▲ +0.99% −0.28% vs SPY
- Sep 8, 202610w ago 8-K Bullish 5/10 Entry $184.73 to $194.86 Now $194.38 +5.22% ▲ +5.48% +6.15% vs SPY
- Aug 24, 202612w ago 8-K Neutral 3/10 Entry $191.46 to $187.30 Now $194.38 +1.53% ▼ −2.17% −2.64% vs SPY
- Aug 3, 202615w ago 25-NSE Neutral 1/10 Entry $187.41 to $186.00 Now $194.38 +3.72% ▼ −0.75% −2.78% vs SPY
- Jul 22, 202616w ago 8-K Bullish 7/10 Viewing Entry $194.30 to $198.44 Now $194.38 +0.04% ▲ +2.13% +4.53% vs SPY
- Jun 29, 202620w ago 8-K Neutral 3/10 Entry $180.91 to $184.76 Now $194.38 +7.45% ▲ +2.13% +1.52% vs SPY
- Jun 11, 202622w ago 8-K Neutral 2/10 Entry $180.77 to $179.44 Now $194.38 +7.53% ▼ −0.74% −1.17% vs SPY
- May 20, 202625w ago 8-K Neutral 3/10 Entry $187.72 to $178.51 Now $194.38 +3.55% ▼ −4.91% −6.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers